EXIRIS S R L has a total of 17 patent applications. It increased the IP activity by 200.0%. Its first patent ever was published in 2015. It filed its patents most often in EPO (European Patent Office), Australia and Canada. Its main competitors in its focus markets pharmaceuticals and biotechnology are BIOCLIN THERAPEUTICS INC, HANSEN HANS J and HEIDELBERG IMMUNOTHERAPEUTICS GMBH.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 4 | |
#2 | Australia | 2 | |
#3 | Canada | 2 | |
#4 | China | 2 | |
#5 | Republic of Korea | 2 | |
#6 | WIPO (World Intellectual Property Organization) | 2 | |
#7 | Brazil | 1 | |
#8 | Israel | 1 | |
#9 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Osswald Bianca | 8 |
#2 | Ritzefeld Markus | 8 |
#3 | Frese Marcel | 8 |
#4 | Sewald Norbert | 8 |
#5 | Gallinari Paola | 8 |
#6 | Filocamo Gessica | 7 |
#7 | Steinkuhler M Christian | 7 |
#8 | Paolini Chantal | 7 |
#9 | Lahm Armin | 7 |
#10 | Gallinari M Paola | 7 |
Publication | Filing date | Title |
---|---|---|
EP3444275A1 | Monoclonal antibody anti-fgfr4 | |
EP3069734A1 | Cryptophycin-based antibody-drug conjugates with novel self-immolative linkers |